Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Acclaimed by its peers the world over, Gustave Roussy is once again among the world's top 5 cancer institutes, in 4th place in the ranking of cancer hospitals published by the American magazine Newsweek for the year 2024. This position, after three of the most prestigious American centers, positions Gustave Roussy as a world leader in oncology, and reflects the Institute's international standing, both in terms of research integrated into care and technological innovations deployed in the service of patients living with cancer.
The "World's Best Specialized Hospital" ranking, published annually by Newsweek magazine and Statista, identifies and ranks the world's best hospitals in 12 disciplines, including oncology. For 2024, Gustave Roussy ranks 4th among the world's best cancer hospitals. The ranking is based on the results of an online survey of tens of thousands of leading healthcare experts, and draws on quality indicators as expressed by patients.
"First in France, first in Europe and fourth in the world, we are extremely proud that Gustave Roussy is the French champion of oncology on the international stage. Our recurrent presence in the Top 5 in 2024 is the fruit of the investment and efforts of all the Institute's professionals, mobilized to offer the very best in innovation to cure cancer in the 21st century", comments Pr Fabrice Barlesi, CEO of Gustave Roussy.
A pioneer and leader in surgery, radiotherapy, immunotherapy and precision medicine, recognized as a major player worldwide for its ability to deploy early trials, the Institute boasts the largest number of oncology researchers on the prestigious "highly cited researchers" list, and boasts many physician-researchers who regularly receive awards at international congresses or head up international learned societies; a result that reflects the excellence of the research and innovation work carried out at Gustave Roussy.
"This 4th place worldwide reflects our commitment to our patients. We are constantly striving to improve so that, in addition to treatment, we can offer them the best possible care pathways. This is Gustave Roussy's ambition, with massive investments to build around the Institute and the Paris-Saclay Cancer Cluster, the largest European campus dedicated to cancer, with the challenge of health independence in cancerology for France; notably with the construction of new buildings dedicated to personalized prevention and rapid cancer diagnosis, a new research center, but also through the ambitious renovation program for our hospitalization units," adds Prof. Fabrice Barlesi, Gustave Roussy's CEO.
► Consult the ranking and methodology
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
